Current update on eosinophilic lung diseases and anti-IL-5 treatment

Recent Pat Antiinfect Drug Discov. 2011 Sep 1;6(3):189-205. doi: 10.2174/157489111796887855.


Peripheral blood eosinophilia and eosinophilic lung inflammation are common in a variety of pulmonary conditions, including eosinophilic pneumonia and asthma, hypereosinophilic syndrome and Churg-Strauss syndrome. Therapy in most of these clinical entities consists of long-term treatment with systemic corticosteroids, which is not always successful and has substantial side-effects. Interest has increased considerably regarding alternative corticosteroid-sparing "smart" regimens in these diseases that target IL-5, an important regulator of eosinophilic development and function. To date, two humanized monoclonal antibodies, mepolizumab and reslizumab, have been developed that bind to human IL-5. In addition a new monoclonal antibody (MEDI-563) has been recently developed targeting the IL-5 receptor. This review will investigate the current status on IL-5 targeted therapy and related patents regarding eosinophil-driven respiratory diseases, primarily eosinophilic asthma but also CSS and HES. Recent advances and information from clinical trials will be presented in a way that will allow the reader to approach the role of the eosinophil in the lung diseases presented in this review.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Churg-Strauss Syndrome / drug therapy
  • Churg-Strauss Syndrome / immunology
  • Churg-Strauss Syndrome / pathology
  • Drug Delivery Systems / trends*
  • Eosinophilia / drug therapy*
  • Eosinophilia / immunology
  • Eosinophils / drug effects
  • Eosinophils / immunology
  • Humans
  • Interleukin-5 / antagonists & inhibitors*
  • Interleukin-5 / immunology*
  • Lung Diseases / drug therapy*
  • Lung Diseases / immunology
  • Pulmonary Eosinophilia / drug therapy
  • Pulmonary Eosinophilia / immunology
  • Pulmonary Eosinophilia / pathology
  • Treatment Outcome


  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Interleukin-5
  • mepolizumab